GHLF supports KY SB 134

SB 134 takes positive steps toward updating Kentucky law to cover biologics and biosimilars in a way that protects patients. As you know, unlike traditional chemical drugs, biologics are unique, complex structures made from living cells that are not easily replicated. A small change or difference in the biosimilar or biologic manufacturing process has the potential to adversely impact the patient.

There are four provisions in SB 134 that GHLF believes are key to ensuring patients’ safety and needs are met in the best way possible.

Click Here to read the full letter